In patients with dementia and Alzheimer’s disease, CYP2C9 is just one of several genes where the geno-phenotypes are involved in drug metabolism across several classes of drugs currently used to improve overall neurocognitive function [44, 45]. Here, CYP2C9 is linked to early-onset autosomal dominant Alzheimer disease.